Cannabis specialist GW Pharma ramps up capacity ahead of key drug approval

Warning message

The subscription service is currently unavailable. Please try again later.

Pharmaceuticals firm hopes to get positive results from key trials next year, paving the way for the regulatory green light

GW Pharmaceuticals, which makes drugs derived from the cannabis plant, is scaling up its manufacturing capacity ahead of an expected approval of a new treatment for children with life-threatening epilepsy.

Chief executive Justin Gover said production in 2015 had already increased by 20 times and that this was expected to double further in 2016 to meet "significant" commercial demand for Epidiolex, if it is approved by the US Food and Drug Administration. Some analysts believe the drug could get the green light in early 2017. 

This upscaling will equate to roughly 200 tonnes of raw material a year - in the form of specially grown cannabis plants. When purified and formulated, it will result in 1.6 million 100mg bottles of Epidiolex, enough to supply 55,000 seriously ill children for a...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.